20
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Zinc and COVID-19: Basis of Current Clinical Trials

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Coronavirus disease-2019 (COVID-19) pandemic continues to threaten patients, societies, and economic and healthcare systems around the world. Like many other diseases, the host immune system determines the progress of COVID-19 and fatality. Modulation of inflammatory response and cytokine production using immunonutrition is a novel concept that has been applied to other diseases as well. Zinc, one of the anti-inflammatory and antioxidant micronutrient found in food with well-established role in immunity, is currently being used in some clinical trials against COVID-19. This review integrates the contemporary studies of role of zinc in antiviral immunity along with discussing its potential role against COVID-19, and ongoing COVID-19 clinical trials using zinc.

          Related collections

          Most cited references77

          • Record: found
          • Abstract: found
          • Article: not found

          Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

          Summary Viral pandemics, such as the one caused by SARS-CoV-2, pose an imminent threat to humanity. Because of its recent emergence, there is a paucity of information regarding viral behavior and host response following SARS-CoV-2 infection. Here we offer an in-depth analysis of the transcriptional response to SARS-CoV-2 compared with other respiratory viruses. Cell and animal models of SARS-CoV-2 infection, in addition to transcriptional and serum profiling of COVID-19 patients, consistently revealed a unique and inappropriate inflammatory response. This response is defined by low levels of type I and III interferons juxtaposed to elevated chemokines and high expression of IL-6. We propose that reduced innate antiviral defenses coupled with exuberant inflammatory cytokine production are the defining and driving features of COVID-19.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The pathogenesis and treatment of the `Cytokine Storm' in COVID-19

            Summary Cytokine storm is an excessive immune response to external stimuli. The pathogenesis of the cytokine storm is complex. The disease progresses rapidly, and the mortality is high. Certain evidence shows that, during the coronavirus disease 2019 (COVID-19) epidemic, the severe deterioration of some patients has been closely related to the cytokine storm in their bodies. This article reviews the occurrence mechanism and treatment strategies of the COVID-19 virus-induced inflammatory storm in attempt to provide valuable medication guidance for clinical treatment.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study

              Abstract Objective To evaluate viral loads at different stages of disease progression in patients infected with the 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the first four months of the epidemic in Zhejiang province, China. Design Retrospective cohort study. Setting A designated hospital for patients with covid-19 in Zhejiang province, China. Participants 96 consecutively admitted patients with laboratory confirmed SARS-CoV-2 infection: 22 with mild disease and 74 with severe disease. Data were collected from 19 January 2020 to 20 March 2020. Main outcome measures Ribonucleic acid (RNA) viral load measured in respiratory, stool, serum, and urine samples. Cycle threshold values, a measure of nucleic acid concentration, were plotted onto the standard curve constructed on the basis of the standard product. Epidemiological, clinical, and laboratory characteristics and treatment and outcomes data were obtained through data collection forms from electronic medical records, and the relation between clinical data and disease severity was analysed. Results 3497 respiratory, stool, serum, and urine samples were collected from patients after admission and evaluated for SARS-CoV-2 RNA viral load. Infection was confirmed in all patients by testing sputum and saliva samples. RNA was detected in the stool of 55 (59%) patients and in the serum of 39 (41%) patients. The urine sample from one patient was positive for SARS-CoV-2. The median duration of virus in stool (22 days, interquartile range 17-31 days) was significantly longer than in respiratory (18 days, 13-29 days; P=0.02) and serum samples (16 days, 11-21 days; P<0.001). The median duration of virus in the respiratory samples of patients with severe disease (21 days, 14-30 days) was significantly longer than in patients with mild disease (14 days, 10-21 days; P=0.04). In the mild group, the viral loads peaked in respiratory samples in the second week from disease onset, whereas viral load continued to be high during the third week in the severe group. Virus duration was longer in patients older than 60 years and in male patients. Conclusion The duration of SARS-CoV-2 is significantly longer in stool samples than in respiratory and serum samples, highlighting the need to strengthen the management of stool samples in the prevention and control of the epidemic, and the virus persists longer with higher load and peaks later in the respiratory tissue of patients with severe disease.
                Bookmark

                Author and article information

                Contributors
                maximus1134@gmail.com , amit.biochem@aiimskalyani.edu.in
                Journal
                Biol Trace Elem Res
                Biol Trace Elem Res
                Biological Trace Element Research
                Springer US (New York )
                0163-4984
                1559-0720
                22 October 2020
                : 1-11
                Affiliations
                [1 ]GRID grid.413618.9, ISNI 0000 0004 1767 6103, Department of Biochemistry, , All India Institute of Medical Sciences (AIIMS), ; Kalyani, West Bengal 741245 India
                [2 ]GRID grid.419422.8, Molecular Markers Laboratory, , IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, ; Brescia, Italy
                [3 ]GRID grid.417778.a, ISNI 0000 0001 0692 3437, Neuroimmunology Unit, , IRCSS Fondazione Santa Lucia, ; 00143 Rome, Italy
                [4 ]GRID grid.472261.4, ISNI 0000 0004 5376 7555, Department of Zoology, , DAV University, ; Jalandhar, Punjab, India
                [5 ]GRID grid.425670.2, ISNI 0000 0004 1763 7550, Department of Laboratory Medicine, Research and Development Division, , San Giovanni Calibita Fatebenefratelli Hospital, Isola Tiberina, ; Rome, Italy
                [6 ]GRID grid.413618.9, ISNI 0000 0004 1767 6103, Department of Biochemistry, , AIIMS, ; Jodhpur, Rajasthan, India
                [7 ]Department of Biochemistry, MM Institute of Medical Sciences and Research, Mullana, Ambala 133207, Haryana, India
                Author information
                https://orcid.org/0000-0001-9916-3309
                Article
                2437
                10.1007/s12011-020-02437-9
                7580816
                33094446
                0ab5f51e-8d5a-42dc-bf40-6eec7ffdd2c5
                © Springer Science+Business Media, LLC, part of Springer Nature 2020

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                History
                : 13 August 2020
                : 11 October 2020
                Categories
                Article

                Biochemistry
                covid-19,clinical trials,immunity,zinc
                Biochemistry
                covid-19, clinical trials, immunity, zinc

                Comments

                Comment on this article